Shanghai Jikai Bio has secured Series C financing led by Fengshang Capital to enhance its R&D in cosmetic ingredients, reflecting strong investor confidence in the booming domestic beauty market.
Target Information
Shanghai Jikai Biological Technology Co., Ltd. ("Jikai Bio") was established in 2010 and focuses on the research and development of functional ingredients for cosmetics. The company prioritizes technological innovation and product development, aiming to meet the diverse needs of the beauty and personal care industry. With a commitment to creating high-quality and effective cosmetic raw materials, Jikai Bio is positioned as a key player in the market.
The company recently completed a Series C financing round, bolstered by continued investment from Fengshang Capital, which will support Jikai Bio in its next growth phase and enhance its operational capabilities.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The cosmetics industry in China has seen rapid growth over the years, driven by rising consumer demand and the increasing popularity of beauty products. This growth is further amplified by the country's burgeoning middle class, which is
Similar Deals
温氏资本和华熙朗亚
invested in
上海珈凯生物科技有限公司
in 2022
in a Other deal
Disclosed details
Transaction Size: $85M
Enterprise Value: $85M
Equity Value: $85M